Our Mission

The work requires a particular
kind of impatience.

Founder & CEO

Alexandre Martinez, MD, MPH

Alexandre Martinez is a physician-scientist with training in internal medicine. His work sits at the convergence of clinical medicine, artificial intelligence, and genomic science — specifically the question of whether aging-related organ failure can be intercepted at the cellular level.

Before founding Argead, he trained at institutions where the distance between bedside observation and laboratory intervention was deliberately short. That proximity — between what patients experience and what biology permits — is the intellectual core of the company.

Argead's flagship program targets the intersection of cellular senescence and malignant transformation — two biological processes that are, in many ways, opposing solutions to the same underlying problem. Through integrated genomic and cellular modification strategies, the company is working to intercept the degenerative drift of aging while preserving the tumor suppressor architecture that keeps those interventions safe. That tradeoff — between longevity and oncogenic risk — is the scientific core the company was founded to resolve.

Education, Training & Experience

Founding Chief ResidentSt. Clair Health
Internal Medicine ResidencyUPMC
Doctor of Medicine (MD)Sidney Kimmel Medical College (SKMC)
Master of Public Health (MPH)Jefferson College of Population Health (JCPH)

Research Focus

Cellular Senescence and Aging
Oncology — Lymphoma, Colon Cancer, Prostate Cancer
Electrophysiology

Location

CIC Philadelphia, PA

Co-Founder & CSO

Nicolas Martinez, MS

Nicolas Martinez brings extensive hands-on experience across the full arc of biologics development, from early-stage cell bank manufacturing at GSK to cutting-edge immunotherapy production — including tumor-infiltrating lymphocyte (TIL) manufacturing at WuXi AppTec. His work in cell therapeutics spans the bench-level precision required for adoptive cell therapy manufacturing to the systems-level thinking that keeps complex biological operations on track.

His background also encompasses model organism genetic engineering in C. elegans and the operational infrastructure that holds a research organization together: SOP development, experimental design, and laboratory systems management. That breadth — from the molecular to the procedural — is what Argead's lab operations are built on.

At Argead, Nicolas leads the translation of those disciplines into a working laboratory: building the cell engineering infrastructure, establishing the protocols that will govern iPSC and HSC workflows, and ensuring that the science moves from hypothesis to bench with the rigor that advanced cell therapy demands.